Evidence map›Paper›PMID 39934527›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025

Antifungal activity of guanidine compounds.

Alexandra Daniela Barrios Eguiluz, Caroline Barcelos Costa Orlandi, Rafael Días Do Espírito Santo, Eduardo Henrique Zampieri, Luana Ribeiro Dos Anjos, Maria José Soares Mendes Giannini, Ana Marisa Fusco-Almeida, Sandro Roberto Valentini, Cleslei Fernando Zanelli, Tatiana Maria de Souza-Moreira and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Alexandra Daniela Barrios EguiluzSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Caroline Barcelos Costa OrlandiSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Rafael Días Do Espírito SantoFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University-UNESP, Roberto Simonsen, 305, Presidente Prudente, São Paulo, 19060-080, Brazil.
Eduardo Henrique ZampieriFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University-UNESP, Roberto Simonsen, 305, Presidente Prudente, São Paulo, 19060-080, Brazil.
Luana Ribeiro Dos AnjosFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University-UNESP, Roberto Simonsen, 305, Presidente Prudente, São Paulo, 19060-080, Brazil.
Maria José Soares Mendes GianniniSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Ana Marisa Fusco-AlmeidaSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Sandro Roberto ValentiniSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Cleslei Fernando ZanelliSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Tatiana Maria de Souza-MoreiraSchool of Pharmaceutical Sciences, São Paulo State University-UNESP, Rod. Araraquara-Jau Km 1, Araraquara, São Paulo, 14800-903, Brazil.
Eduardo René Pérez GonzálezFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University-UNESP, Roberto Simonsen, 305, Presidente Prudente, São Paulo, 19060-080, Brazil. eduardo.gonzalez@unesp.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 431455/2018-0Fundação de Amparo à Pesquisa do Estado de São Paulo 14/19793-3Fundação de Amparo à Pesquisa do Estado de São Paulo 16/16970-7Fundação de Amparo à Pesquisa do Estado de São Paulo 17/18388-6
6 · The paper itself

Abstract

Guanidinic compounds are a class of compounds distributed in nature but also synthesized in vitro with a wide variety of applicability. One of the potentials of those molecules is antimicrobial activity. In that sense, although mainly limited to immunocompromised people, fungi pathogens are a cause of concern, even more so after the COVID-19 pandemic. Susceptible groups and increased geographical distribution, besides drug toxicity, resistance, and high costs, made the World Health Organization (WHO) establish a guideline for research and public health politics against different fungi opportunist agents. Our present work evaluated the antifungal activity of 11 guanidine compounds (one of them synthesized for the first time) against six fungi species in the WHO Fungi Priority Pathogens List and their potential for antimicrobial selectivity. The newly synthesized compound, named LQOF-G2-S, was successfully obtained and chemically characterized as spermidine tri-substituted by guanidine moieties in benzylamine-4-bromoaniline groups, and it presented the best antifungal activity and selectivity among the others. It was the only compound active against Candida spp.; however, its activity was more promising against Cryptococcus neoformans, Cryptococcus gattii, and even more against Paracoccidioides brasiliensis and Paracoccidioides lutzii, with a selective index higher than 10. The LQOF-G2-S potential opened up the opportunity to design and evaluate other similar compounds, contributing to finding new effective, less toxic, and more affordable compounds for fungi treatment.

Indexed as

Antifungal AgentsFungiGuanidineGuanidinesCandidaHumansMicrobial Sensitivity TestsAntifungal AgentsGuanidineGuanidinesCandidaCytotoxicitySpermidineWHO fungi priority pathogens list

Identifiers

PMID39934527
PMCPMC12095743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.